Research Article

Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.

Br Med J (Clin Res Ed) 1983; 286 doi: http://dx.doi.org/10.1136/bmj.286.6374.1309 (Published 23 April 1983) Cite this as: Br Med J (Clin Res Ed) 1983;286:1309
  1. J H Waxman,
  2. J A Wass,
  3. W F Hendry,
  4. H N Whitfield,
  5. G M Besser,
  6. J S Malpas,
  7. R T Oliver

    Abstract

    Repeated administration of long acting analogues of gonadotrophin releasing hormone diminishes gonadal function and in men decreases testosterone concentrations; for this reason the effect of the analogue buserelin was studied in prostatic carcinoma. Twelve consecutive patients with newly diagnosed locally advanced or metastatic carcinoma of the prostate were treated. Each patient received intranasal buserelin in divided dosages of either 600 or 1000 micrograms daily. Suppression of the gonadotrophins and testosterone occurred in all patients. Objective and subjective signs of regression of disease were seen in nine patients. Buserelin offers an effective treatment of metastatic prostatic cancer without the side effects and cardiovascular risks associated with oestrogen treatment.